These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27040854)

  • 41. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
    Demierre N; Zoete V; Michielin O; Stauffer E; Zimmermann DR; Betticher DC; Peters S
    Lung Cancer; 2013 Apr; 80(1):81-4. PubMed ID: 23380224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery.
    Helland Å; Skaug HM; Kleinberg L; Iversen ML; Rud AK; Fleischer T; Sagerup C; Solberg S; Jørgensen L; Ariansen S; Brustugun OT
    J Thorac Oncol; 2011 May; 6(5):947-50. PubMed ID: 21623266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.
    Stone E; Allen HA; Saghaie T; Abbott A; Daniel R; Mead RS; Kohonen-Corish M; Plit M; Morgan L
    Intern Med J; 2014 Dec; 44(12a):1188-92. PubMed ID: 25228365
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synchronous primary lung cancer presenting with small cell carcinoma and adenocarcinoma.
    Yamamoto Y; Kodama K; Yamato H; Takeda M; Takamori H; Karasuno T
    Ann Thorac Cardiovasc Surg; 2015; 21(2):183-7. PubMed ID: 25832826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study.
    Thomas A; Mian I; Tlemsani C; Pongor L; Takahashi N; Maignan K; Snider J; Li G; Frampton G; Ali S; Kim S; Nichols S; Rajapakse V; Guha U; Sharon E; Fujimoto J; Moran CA; Wistuba II; Wei JS; Khan J; Szabo E; Torres AZ; Carson KR
    Chest; 2020 Oct; 158(4):1723-1733. PubMed ID: 32464188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.
    Hochmair MJ; Illini O; Prosch H; Krenbek D; Valipour A
    Clin Lung Cancer; 2022 Jun; 23(4):e289-e292. PubMed ID: 34865962
    [No Abstract]   [Full Text] [Related]  

  • 54. Small cell lung cancer elevates procalcitonin levels in the absence of infection.
    Pardo-Cabello AJ; Manzano-Gamero V
    Lung Cancer; 2019 Aug; 134():272-273. PubMed ID: 31235317
    [No Abstract]   [Full Text] [Related]  

  • 55. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].
    Oncology Society of Chinese Medical Association
    Zhonghua Yi Xue Za Zhi; 2024 Sep; 104(34):3175-3213. PubMed ID: 39193605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.
    Wang Q; Gümüş ZH; Colarossi C; Memeo L; Wang X; Kong CY; Boffetta P
    J Thorac Oncol; 2023 Jan; 18(1):31-46. PubMed ID: 36243387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity.
    Zullo L; Dall'Olio FG; Rossi G; Dellepiane C; Barletta G; Bennicelli E; Ingaliso M; Tagliamento M; Genova C
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small-cell lung cancer exhibiting spontaneous regression.
    Iwakami S; Fujii M; Ishiwata T; Iwakami N; Hara M; Ihara H; Wada R; Tsutsumi T; Seyama K; Takahashi K
    Intern Med; 2013; 52(19):2249-52. PubMed ID: 24088761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Looking ahead to new therapies in small cell lung cancer.
    Rudin CM
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):269-272. PubMed ID: 29742081
    [No Abstract]   [Full Text] [Related]  

  • 60. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
    Ju L; Han M; Zhao C; Li X
    Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.